ASH 2018 | Vecabrutinib for B-lymphoid malignancies

Susan O’Brien

Ibrutinib, a BTK inhibitor, is an excellent option for the treatment of B-lymphoid cancers; however, patients eventually become refractory due to the development of resistance. Here, Susan O’Brien, MD, of the University of California, Irvine, CA, provides an overview of the use of vecabrutinib, a next-generation competitive BTK inhibitor, which should prevent the acquisition of resistance. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien highlights the Phase I dose escalation study (NCT03037645) evaluating the clinical activity, safety and pharmacodynamics of this treatment.

Share this video